
Overview

Useful For

Diagnosis and differential diagnosis of hyperandrogenism (in conjunction with measurements of other sex-steroids). An initial workup in adults might also include total and bioavailable testosterone (TTBS / Testosterone, Total and Bioavailable, Serum) measurements. Depending on results, this may be supplemented with measurements of sex hormone-binding globulin (SHBG / Sex Hormone Binding Globulin [SHBG], Serum) and other androgenic steroids (eg, dehydroepiandrosterone sulfate [DHEA-S]).

Diagnosis of congenital adrenal hyperplasia (CAH), in conjunction with measurement of other androgenic precursors, particularly, 17-alpha-hydroxyprogesterone (OHPG) (OHPG / 17-Hydroxyprogesterone, Serum), 17 alpha-hydroxypregnenolone, DHEA-S (DHES / Dehydroepiandrosterone Sulfate [DHEA-S], Serum), and cortisol (CORT / Cortisol, Serum).

Monitoring CAH treatment, in conjunction with testosterone (TTST / Testosterone, Total, Serum), OHPG (OHPG / 17-Hydroxyprogesterone, Serum), DHEA-S (DHES / Dehydroepiandrosterone Sulfate [DHEA-S], Serum), and DHEA (DHEA_ / Dehydroepiandrosterone [DHEA], Serum).

Diagnosis of premature adrenarche, in conjunction with gonadotropins (FSH / Follicle-Stimulating Hormone [FSH], Serum; LH / Luteinizing Hormone [LH], Serum) and other adrenal and gonadal sex-steroids and their precursors (TTBS / Testosterone, Total and Bioavailable, Serum or TGRP / Testosterone, Total and Free, Serum; EEST / Estradiol, Serum; DHES / Dehydroepiandrosterone Sulfate [DHEA-S], Serum; DHEA_ / Dehydroepiandrosterone [DHEA], Serum; SHBG / Sex Hormone Binding Globulin [SHBG], Serum; OHPG / 17-Hydroxyprogesterone, Serum).

Testing Algorithm

See [Steroid Pathways](#) in Special Instructions.

Special Instructions

- [Steroid Pathways](#)

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

NY State Available

Yes

Specimen

Specimen Type

Serum Red

Specimen Required

Container/Tube: Red top

Specimen Volume: 0.6 mL

Reject Due To

| | |
|-----------------|----------------|
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | OK |
| Other | Serum gel tube |

Specimen Minimum Volume

0.25 mL

Specimen Stability Information

| Specimen Type | Temperature | Time | Special Container |
|---------------|--------------------------|---------|-------------------|
| Serum Red | Refrigerated (preferred) | 28 days | |
| | Frozen | 28 days | |
| | Ambient | 7 days | |

Clinical & Interpretive

Clinical Information

Androstenedione is secreted predominately by the adrenal gland and production is at least partly controlled by adrenocorticotrophic hormone (ACTH). It is also produced ACTH-independent in the testes and ovaries from adrenal-secreted dehydroepiandrosterone sulfate (DHEA-S). Androstenedione is a crucial sex-steroid precursor. It lies at the convergence of the 2 biosynthetic pathways that lead from the progestins to the sex-steroids, being derived either via:

-C3-dehydrogenation of dehydroepiandrosterone (DHEA)

-Catalyzed by 3-beta-hydroxysteroid dehydrogenase-2 (adrenals and gonads)

-17,20-lyase (*CYP17A1*)-mediated side-chain cleavage of 17-alpha-hydroxyprogesterone (OHPG)

Androstenedione production during life mimics the pattern of other androgen precursors. Fetal serum concentrations increase throughout embryonal development and peak near birth at approximately young adult levels. Levels then fall rapidly during the first year of life to low prepubertal values. With the onset of adrenarche, androstenedione rises gradually, a process that accelerates with the onset of puberty, reaching adult levels around age 18. Adrenarche is a poorly understood phenomenon peculiar to higher primates that is characterized by a gradual rise in adrenal androgen production. It precedes puberty, but is not causally linked to it. Early adrenarche is not associated with early puberty, or with any reduction in final height, or overt androgenization, and is generally regarded as a benign condition not requiring intervention. However, girls with early adrenarche may be at increased risk of polycystic ovarian syndrome as adults, and some boys may develop early penile enlargement.

Elevated androstenedione levels can cause symptoms or signs of hyperandrogenism in women. Men are usually asymptomatic, but through peripheral conversion of androgens to estrogens can occasionally experience mild symptoms of estrogen excess, such as gynecomastia.

Most mild-to-moderate elevations in androstenedione are idiopathic. However, pronounced elevations of androstenedione may be indicative of androgen-producing adrenal or gonadal tumors.

In children, adrenal and gonadal tumors are uncommon, but many forms of congenital adrenal hyperplasia can increase serum androstenedione concentrations. Diagnosis always requires measurement of other androgen precursors (eg, OHPG, 17-alpha-hydroxypregnenolone, and DHEA-S) and cortisol, in addition to androstenedione.

See [Steroid Pathways](#) in Special Instructions.

Reference Values

PEDIATRICS*

Premature infants

26-28 weeks, day 4: 92-282 ng/dL

31-35 weeks, day 4: 80-446 ng/dL

Full-term infants

1-7 days: 20-290 ng/dL

1 month-1 year: <69 ng/dL

Males*

| Tanner Stages | Age (Years) | Reference Range (ng/dL) |
|--------------------------|-------------|-------------------------|
| Stage I (prepubertal) | <9.8 | <51 |
| Stage II | 9.8-14.5 | 31-65 |
| Stage III | 10.7-15.4 | 50-100 |
| Stage IV | 11.8-16.2 | 48-140 |
| Stage V | 12.8-17.3 | 65-210 |

Females*

| Tanner Stages | Age (Years) | Reference Range (ng/dL) |
|--------------------------|-------------|-------------------------|
| Stage I (prepubertal) | <9.2 | <51 |
| Stage II | 9.2-13.7 | 42-100 |
| Stage III | 10.0-14.4 | 80-190 |
| Stage IV | 10.7-15.6 | 77-225 |
| Stage V | 11.8-18.6 | 80-240 |

*Source: Androstenedione. *In* Pediatric Reference Ranges. Fourth edition. Edited by SJ Soldin, C Brugnara, EC Wong. Washington, DC, AACC Press, 2003, pp 32-34

ADULTS

Males: 40-150 ng/dL

Females: 30-200 ng/dL

For SI unit Reference Values, see <https://www.mayocliniclabs.com/order-tests/si-unit-conversion.html>

Interpretation

Elevated androstenedione levels indicate increased adrenal or gonadal androgen production. Mild elevations in adults are usually idiopathic, or related to conditions such as polycystic ovarian syndrome (PCOS) in women, or use of androstenedione supplements in men and women. However, levels greater than or equal to 500 ng/dL can suggest the presence of an androgen-secreting adrenal, or less commonly, a gonadal, tumor. Androstenedione levels are elevated in more than 90% of patients with benign androgen-producing adrenal tumors, usually well above 500 ng/dL. Most androgen-secreting adrenal carcinomas also exhibit elevated androstenedione levels, but more typically show relatively larger elevations in 17-alpha-hydroxyprogesterone (OHPG) and dehydroepiandrosterone sulfate (DHEA-S) than in androstenedione, as they have often lost the ability to produce downstream androgens.

Most androgen-secreting gonadal tumors also overproduce androstenedione, but often to lesser degrees than adrenal tumors. They also overproduce testosterone. In men and in women with high baseline androgen levels (eg, PCOS), the respective elevations of androstenedione and testosterone may not be high enough to allow unequivocal diagnosis of androgen-producing gonadal tumors. In these cases, an elevation of the usual ratio of testosterone to androstenedione of 1, to a ratio of >1.5, is a strong indicator of neoplastic androgen production.

Diagnosis and differential diagnosis of congenital adrenal hyperplasia (CAH) always requires the measurement of several steroids. Patients with CAH due to 21-hydroxylase gene (*CYP21A2*) mutations the most common cause of CAH (>90% of cases), usually have very high levels of androstenedione, often 5- to 10-fold elevations. OHPG levels are usually even higher, while cortisol levels are low or undetectable. All 3 analytes should be tested.

In the much less common *CYP11A1* mutation, androstenedione levels are elevated to a similar extent as in *CYP21A2* mutation, and cortisol is also low, but OHPG is only mildly, if at all, elevated.

Also less common, 3 beta HSD-2 deficiency is characterized by low cortisol and substantial elevations in DHEA-S and 17-alpha-hydroxypregnenolone, while androstenedione is either low, normal, or, rarely, very mildly elevated (as a consequence of peripheral tissue androstenedione production by 3 beta HSD-1).

In the very rare STAR (steroidogenic acute regulatory protein) deficiency, all steroid hormone levels are low and cholesterol is elevated.

In the also very rare 17-alpha-hydroxylase deficiency, androstenedione, all other androgen-precursors (17-alpha-hydroxypregnenolone, OHPG, DHEA-S), androgens (testosterone, estrone, estradiol), and cortisol are low, while production of mineral corticoid and their precursors, in particular progesterone, 11-deoxycorticosterone, corticosterone, and 18-hydroxycorticosterone, are increased.

The goal of CAH treatment is normalization of cortisol levels and, ideally, also of sex-steroid levels. Traditionally, OHPG and urinary pregnanetriol or total ketosteroid excretion are measured to guide treatment, but these tests correlate only modestly with androgen levels. Therefore, androstenedione and testosterone should also be measured and used for treatment modifications. Normal prepubertal levels may be difficult to achieve, but if testosterone levels are within the reference range, androstenedione levels up to 100 ng/dL are usually regarded as acceptable.

Girls below the age of 7 to 8 and boys before age 8 to 9 who present with early development of pubic hair or, in boys, penile enlargement, may be suffering from either premature adrenarche or premature puberty, or both. Measurement of DHEA-S, DHEA, and androstenedione, alongside determination of sensitive estradiol, total and bioavailable or free testosterone, sex hormone binding globulin (SHBG), and luteinizing hormone/follicle-stimulating hormone levels will allow correct diagnosis in most cases. In premature adrenarche, only the adrenal androgens, chiefly DHEA-S, and to a lesser degree, androstenedione, will be above prepubertal levels, whereas early puberty will also show a fall in SHBG levels and variable elevations of gonadotropins and gonadal sex-steroids above the prepuberty reference range.

See [Steroid Pathways](#) in Special Instructions.

Cautions

Any condition that can result in partial or complete adrenal or gonadal failure may result in low androstenedione levels, diminishing the diagnostic usefulness of the test in these settings.

Androstenedione and, to a lesser degree, dehydroepiandrosterone sulfate (DHEA-S) supplements can result in elevations of serum androstenedione level. With large androstenedione doses of 300 to 400 mg/day, serum androstenedione levels can almost double in some patients. Testosterone levels and, particularly in men, estrone and estradiol levels, may also increase, but to a much lesser degree.

Although compared with DHEA-S, less information has been published with regard to the effects of hormones and drugs on androstenedione levels, it is likely that many drugs and hormones can result in changes in androstenedione levels. In particular, agents that induce hepatic enzymes, drugs that affect lipid metabolism, and other steroid hormones are likely to affect androstenedione levels, more commonly resulting in lowered levels. Whether any of these secondary changes are of clinical significance and how they should be related to the established normal reference ranges is unknown. In most cases, the drug-induced changes are not large enough to cause diagnostic confusion.

Supportive Data

To establish pediatric reference ranges, we compared adult levels obtained with our liquid chromatography-tandem mass spectrometry methodology with adult levels obtained in other labs with their respective methodologies. We found excellent correlation ($R=0.92$, regression-trendline slope 1.07) with an extracted radioimmunoassay (RIA) method with preanalytical Sephadex column chromatography. This is the method used in Pediatric Reference Ranges Fourth edition, reference number 3 (Esoterix Endocrinology) and is based on Bidlingmaier, Wagner-Barnack, Butenandt, Knorr: Pediatric Research 1973;7:901-907. The ranges were further verified by comparison with another pediatric reference range publication, which used the same extracted RIA method with Sephadex column chromatography.(1)

Clinical Reference

1. Von Schnakenburg K, Bidlingmaier F, Knorr D: 17-hydroxyprogesterone, androstenedione, and testosterone in normal children and in prepubertal patients with congenital adrenal hyperplasia. Eur J Pediatr 1980;133:259-267

-
2. Sciarra F, Tosti-Croce C, Toscano V: Androgen-secreting adrenal tumors. *Minerva Endocrinol* 1995;20:63-68
 3. Young WF Jr: Management approaches to adrenal incidentalomas-a view from Rochester, Minnesota. *Endocrinol Metab Clin North Am* 2000;29:159-185
 4. Ibanez L, DiMartino-Nardi J, Potau N, Saenger P: Premature adrenarche-normal variant or forerunner of adult disease? *Endocr Rev* 2000;21:671-696
 5. Collett-Solberg P: Congenital adrenal hyperplasia: from genetics and biochemistry to clinical practice, part I. *Clin Pediatr* 2001;40:1-16
 6. Allolio B, Arlt W: DHEA treatment: myth or reality? *Trends Endocrinol Metab* 2002;13:288-294

Performance

Method Description

Deuterated stable isotope (d7-androstenedione) is added to a 0.1-mL plasma sample as internal standard. Androstenedione and the internal standard are extracted from specimens using a solid-phase cartridge and eluted from the cartridge with methanol. The extracts are then dried down under nitrogen, reconstituted with 75 mL of 70/30 methanol/H₂O containing 1 mcg/mL of estriol to prevent adsorption to equipment components and analyzed by liquid chromatography-tandem mass spectrometry using multiple-reaction monitoring. (Taylor RL, Machacek D, Singh RJ: Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. *Clin Chem* 2002;48[9]:1511-1519)

PDF Report

No

Specimen Retention Time

14 days

Performing Laboratory Location

Rochester

Fees & Codes

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82157

LOINC® Information

| Test ID | Test Order Name | Order LOINC Value |
|---------|--------------------|-------------------|
| ANST | Androstenedione, S | 1854-9 |

| Result ID | Reporting Name | LOINC® |
|-----------|--------------------|--------|
| 7730 | Androstenedione, S | 1854-9 |